[SCHEDULE 13G/A] NewAmsterdam Pharma Company N.V. Warrant SEC Filing

Rhea-AI Filing Summary

Schedule 13G/A filed for NewAmsterdam Pharma Company N.V. Capital World Investors reports beneficial ownership of 8,387,725 shares, equal to 7.5% of the 112,270,677 shares believed outstanding. The filing states CWI is a division of Capital Research and Management Company and related investment management entities and that these shares are held in the ordinary course of business and not to influence control of the issuer.

The statement shows CWI has sole voting and sole dispositive power over all 8,387,725 shares. The issuer is NewAmsterdam Pharma Company N.V., and CWI's principal business address is 333 South Hope Street, Los Angeles, California. The filing identifies CWI as organized in Delaware.

Positive

• Institutional ownership disclosed: Capital World Investors reports beneficial ownership of 8,387,725 shares (7.5%).
• Sole voting and dispositive power: Filer reports sole power to vote and sole power to dispose of all 8,387,725 shares.

Negative

• None.

Insights

Financial Analyst

TL;DR: Institutional investor discloses a material 7.5% passive stake; routine but material ownership disclosure.

The filing documents that Capital World Investors holds 8,387,725 shares, representing 7.5% of the 112,270,677 shares believed outstanding. This meets the regulatory threshold requiring disclosure and signals meaningful institutional ownership without an expressed intent to change control. For investors, the numeric detail—share count and percent of class—is the core take-away; there are no additional transactions, debt, or earnings data in this filing to alter valuation models. Impact is primarily informational rather than operational.

Corporate Governance Expert

TL;DR: Ownership is reported as passive with sole voting/dispositive power; no control intent declared.

The Schedule 13G/A explicitly states the securities were "acquired and are held in the ordinary course of business" and "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control" of NewAmsterdam Pharma. The report lists sole voting and dispositive power for all disclosed shares, which is relevant for governance monitoring. Absent indications of a group or coordinated action, this is a compliance disclosure rather than an activist or control-seeking filing.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

NewAmsterdam Pharma Company N.V.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

N62509109

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. N62509109

1

Names of Reporting Persons

Capital World Investors

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 8,387,725.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 8,387,725.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,387,725.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.5 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: NewAmsterdam Pharma Company N.V.
(b)	Address of issuer's principal executive offices: Gooimeer 2-35, Naarden 1411 DC, Netherlands
Item 2.
(a)	Name of person filing: Capital World Investors
(b)	Address or principal business office or, if none, residence: 333 SOUTH HOPE STREET, 55TH FLOOR, LOS ANGELES, CALIFORNIA 90071
(c)	Citizenship: N/A
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: N62509109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 8,387,725 ** **Capital World Investors ("CWI") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CWI's divisions of each of the investment management entities collectively provide investment management services under the name "Capital World Investors." CWI is deemed to be the beneficial owner of 8,387,725 shares or 7.5% of the 112,270,677 shares believed to be outstanding.
(b)	Percent of class: 7.5 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 8,387,725
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 8,387,725
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. SMALLCAP World Fund, Inc.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Capital World Investors

Signature:	Timothy J. Moon
Name/Title:	Vice President and Senior Counsel, Capital Research and Management Company
Date:	08/04/2025

FAQ

Who filed the Schedule 13G/A for NewAmsterdam Pharma (NAMSW)?

Capital World Investors filed the Schedule 13G/A; it is a division of Capital Research and Management Company and related entities.

How many NewAmsterdam Pharma (NAMSW) shares does Capital World Investors report owning?

8,387,725 shares, representing 7.5% of the 112,270,677 shares believed to be outstanding.

Does the filer claim voting or dispositive power over the reported NAMSW shares?

Yes. The filing reports sole voting power and sole dispositive power over all 8,387,725 shares.

Was the stake reported as held to influence control of NAMSW?

No. The filing certifies the securities were acquired and are held in the ordinary course of business and not to influence control of the issuer.

What addresses and organization details are listed in the filing?

Issuer: NewAmsterdam Pharma Company N.V., Gooimeer 2-35, Naarden 1411 DC, Netherlands. Filer address: 333 South Hope Street, 55th Floor, Los Angeles, CA 90071. Filer organized in Delaware.